Isolated limb infusion for malignant melanoma: Predictors of response and outcome

Andrew P. Barbour, Janine Thomas, Jennifer Suffolk, Elaine Beller, B. Mark Smithers

Research output: Contribution to journalArticleResearchpeer-review

30 Citations (Scopus)

Abstract

Isolated limb infusion (ILI) is an alternative to isolated limb perfusion (ILP) for the treatment of unresectable limb melanoma recurrence. The aims of this study were to determine the response rates of unresectable local and/or in-transit melanoma of the upper or lower limb to ILI and to identify factors predictive of survival.

A prospective database identified 74 patients (35 male and 39 female) with local and/or in-transit melanoma recurrence without metastatic disease who underwent hyperthermic ILI with melphalan at a single institution between January 1996 and December 2008. Three patients could not be evaluated for response. Median follow-up was 34 months.

Of the 74 patients, the majority had N2c disease (57/74, 67%), while 17/74 (33%) patients had N3 disease. Median maximum temperature achieved was 38.1A degrees C and median tourniquet time was 32.5 min. Wieberdink III/IV complications occurred following 7/74 (10%) ILI and were associated with higher limb volumes and higher total melphalan dose. Complete response (CR) was seen following 17/71 (24%) ILI and the partial response rate was 30% (22/71). The median duration of CR was 43 months. Univariable analyses found that limb volume > 8.0 l and maximum limb temperature > 38.5A degrees C were the only independent factors predictive for a CR following ILI. Multivariate analyses identified CR and positive lymph nodes as the only independent prognostic factors for melanoma-specific survival.

Patients who obtain CR have significantly improved survival compared with nonresponders. The challenge remains to improve CR rates and prospectively identify responders.

Original languageEnglish
Pages (from-to)3463-3472
Number of pages10
JournalAnnals of Surgical Oncology
Volume16
Issue number12
DOIs
Publication statusPublished - Dec 2009
Externally publishedYes

Cite this

Barbour, Andrew P. ; Thomas, Janine ; Suffolk, Jennifer ; Beller, Elaine ; Smithers, B. Mark. / Isolated limb infusion for malignant melanoma : Predictors of response and outcome. In: Annals of Surgical Oncology. 2009 ; Vol. 16, No. 12. pp. 3463-3472.
@article{a339e3360f2043cb95bc3832cca00ac3,
title = "Isolated limb infusion for malignant melanoma: Predictors of response and outcome",
abstract = "Isolated limb infusion (ILI) is an alternative to isolated limb perfusion (ILP) for the treatment of unresectable limb melanoma recurrence. The aims of this study were to determine the response rates of unresectable local and/or in-transit melanoma of the upper or lower limb to ILI and to identify factors predictive of survival.A prospective database identified 74 patients (35 male and 39 female) with local and/or in-transit melanoma recurrence without metastatic disease who underwent hyperthermic ILI with melphalan at a single institution between January 1996 and December 2008. Three patients could not be evaluated for response. Median follow-up was 34 months.Of the 74 patients, the majority had N2c disease (57/74, 67{\%}), while 17/74 (33{\%}) patients had N3 disease. Median maximum temperature achieved was 38.1A degrees C and median tourniquet time was 32.5 min. Wieberdink III/IV complications occurred following 7/74 (10{\%}) ILI and were associated with higher limb volumes and higher total melphalan dose. Complete response (CR) was seen following 17/71 (24{\%}) ILI and the partial response rate was 30{\%} (22/71). The median duration of CR was 43 months. Univariable analyses found that limb volume > 8.0 l and maximum limb temperature > 38.5A degrees C were the only independent factors predictive for a CR following ILI. Multivariate analyses identified CR and positive lymph nodes as the only independent prognostic factors for melanoma-specific survival.Patients who obtain CR have significantly improved survival compared with nonresponders. The challenge remains to improve CR rates and prospectively identify responders.",
author = "Barbour, {Andrew P.} and Janine Thomas and Jennifer Suffolk and Elaine Beller and Smithers, {B. Mark}",
year = "2009",
month = "12",
doi = "10.1245/s10434-009-0717-9",
language = "English",
volume = "16",
pages = "3463--3472",
journal = "Annals of Surgical Oncology",
issn = "1068-9265",
publisher = "Springer",
number = "12",

}

Isolated limb infusion for malignant melanoma : Predictors of response and outcome. / Barbour, Andrew P.; Thomas, Janine; Suffolk, Jennifer; Beller, Elaine; Smithers, B. Mark.

In: Annals of Surgical Oncology, Vol. 16, No. 12, 12.2009, p. 3463-3472.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Isolated limb infusion for malignant melanoma

T2 - Predictors of response and outcome

AU - Barbour, Andrew P.

AU - Thomas, Janine

AU - Suffolk, Jennifer

AU - Beller, Elaine

AU - Smithers, B. Mark

PY - 2009/12

Y1 - 2009/12

N2 - Isolated limb infusion (ILI) is an alternative to isolated limb perfusion (ILP) for the treatment of unresectable limb melanoma recurrence. The aims of this study were to determine the response rates of unresectable local and/or in-transit melanoma of the upper or lower limb to ILI and to identify factors predictive of survival.A prospective database identified 74 patients (35 male and 39 female) with local and/or in-transit melanoma recurrence without metastatic disease who underwent hyperthermic ILI with melphalan at a single institution between January 1996 and December 2008. Three patients could not be evaluated for response. Median follow-up was 34 months.Of the 74 patients, the majority had N2c disease (57/74, 67%), while 17/74 (33%) patients had N3 disease. Median maximum temperature achieved was 38.1A degrees C and median tourniquet time was 32.5 min. Wieberdink III/IV complications occurred following 7/74 (10%) ILI and were associated with higher limb volumes and higher total melphalan dose. Complete response (CR) was seen following 17/71 (24%) ILI and the partial response rate was 30% (22/71). The median duration of CR was 43 months. Univariable analyses found that limb volume > 8.0 l and maximum limb temperature > 38.5A degrees C were the only independent factors predictive for a CR following ILI. Multivariate analyses identified CR and positive lymph nodes as the only independent prognostic factors for melanoma-specific survival.Patients who obtain CR have significantly improved survival compared with nonresponders. The challenge remains to improve CR rates and prospectively identify responders.

AB - Isolated limb infusion (ILI) is an alternative to isolated limb perfusion (ILP) for the treatment of unresectable limb melanoma recurrence. The aims of this study were to determine the response rates of unresectable local and/or in-transit melanoma of the upper or lower limb to ILI and to identify factors predictive of survival.A prospective database identified 74 patients (35 male and 39 female) with local and/or in-transit melanoma recurrence without metastatic disease who underwent hyperthermic ILI with melphalan at a single institution between January 1996 and December 2008. Three patients could not be evaluated for response. Median follow-up was 34 months.Of the 74 patients, the majority had N2c disease (57/74, 67%), while 17/74 (33%) patients had N3 disease. Median maximum temperature achieved was 38.1A degrees C and median tourniquet time was 32.5 min. Wieberdink III/IV complications occurred following 7/74 (10%) ILI and were associated with higher limb volumes and higher total melphalan dose. Complete response (CR) was seen following 17/71 (24%) ILI and the partial response rate was 30% (22/71). The median duration of CR was 43 months. Univariable analyses found that limb volume > 8.0 l and maximum limb temperature > 38.5A degrees C were the only independent factors predictive for a CR following ILI. Multivariate analyses identified CR and positive lymph nodes as the only independent prognostic factors for melanoma-specific survival.Patients who obtain CR have significantly improved survival compared with nonresponders. The challenge remains to improve CR rates and prospectively identify responders.

U2 - 10.1245/s10434-009-0717-9

DO - 10.1245/s10434-009-0717-9

M3 - Article

VL - 16

SP - 3463

EP - 3472

JO - Annals of Surgical Oncology

JF - Annals of Surgical Oncology

SN - 1068-9265

IS - 12

ER -